Marketing Efforts Pay Off As Admedus Ups CardioCel Centers By 50%
A new deal with an aortic ring manufacturer, a change of chairman, a hike in the number of centers using its cardiovascular bioscaffold and plans to develop an aortic valve repair scaffold have attracted much attention to Admedus in the past six months. The Australian company’s immunotherapies platform is also advancing well, says CEO Lee Rodne.
You may also be interested in...
Admedus is mulling over the future of its vaccines business.
Admedus and its product mix was an unfolding success story – and still is, due to a restructuring of activities and a resetting of aims that have ensured the Australia-US tissue engineering company does not miss out on the opportunities it has crafted for itself. Chairman and interim CEO Wayne Paterson explains what changes were required and why.
The much-anticipated return to a “normal” NHS service delivery could yet be dashed by a resurgence of the virus.